Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clemastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 8/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clemastine SCHEMBL4087919 | 1.00 | CHRM3 (1.00) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL23785539 | 1.00 | CHRM3 (1.00) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL727373 | 1.00 | CHRM3 (1.00) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL4058472 | 1.00 | CHRM3 (1.00) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL23785540 | 1.00 | CHRM3 (1.00) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL932384 | 0.99 | CHRM3 (0.98) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL8144354 | 0.93 | CHRM3 (0.87) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL13740733 | 0.93 | CHRM3 (0.87) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL4088016 | 0.93 | CHRM3 (0.87) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL4088154 | 0.93 | CHRM3 (0.87) | CHRM3ADRA1AHRH3CYP3A4CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 19000 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-12569451-B2 | Bio-inspired tissue-adhesive hydrogel patch and uses thereof | Cellartgen Inc. (KR) | 2026-03-10 | — | — | US | claimed |
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | UNIVERSITY OF CINCINNATI (US) | 2026-02-17 | — | — | US | claimed |
| EP-4691492-A2 | LIQUID COMPOSITIONS | Kenvue Brands LLC (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4691568-A2 | LOW-DOSE BRIMONIDINE COMBINATIONS AND USES THEREOF | Eye Therapies, LLC (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4658278-A1 | SELECTIVE FIASMA TREATMENT | Valo Health, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| EP-4640714-A2 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML Screening, LLC (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4630401-A2 | CARBONIC ANHYDRASE ENZYME INHIBITORS AND METHODS OF USE THEREOF | Rutgers, the State University of New Jersey (US) | 2025-10-15 | — | — | EP | claimed |
| EP-0402422-A1 | CERTAIN PAF ANTAGONIST ANTIHISTAMINE COMBINATIONS AND METHODS | SCHERING CORPORATION (US) | 1990-12-19 | — | — | EP | claimed |
| EP-0367746-A2 | Sustained release drug-resin complexes | RICHARDSON-VICKS, INC. (US) | 1990-05-09 | — | — | EP | claimed |
| EP-0345931-A1 | Certain PAF antagonist/antihistamine combinations and methods | SCHERING CORPORATION (US) | 1989-12-13 | — | — | EP | claimed |
| WO-1989010143-A1 | CERTAIN PAF ANTAGONIST ANTIHISTAMINE COMBINATIONS AND METHODS | SCHERING CORPORATION (US) | 1989-11-02 | — | — | WO | claimed |
| EP-0155229-A2 | Pharmaceutical compositions | SANDOZ AG (CH) | 1985-09-18 | — | — | EP | claimed |
| WO-1985003878-A1 | PHARMACEUTICAL COMPOSITIONS | SANDOZ AG (CH) | 1985-09-12 | — | — | WO | claimed |
| EP-0023359-B1 | POWDERY PHARMACEUTICAL COMPOSITION AND POWDERY PREPARATION FOR APPLICATION TO THE NASAL MUCOSA, AND METHOD FOR ADMINISTRATION THEREOF | TEIJIN LIMITED (JP) | 1984-04-18 | — | — | EP | claimed |
| US-4294829-A | Powdery pharmaceutical composition and powdery preparation for application to the nasal mucosa, and method for administration thereof | TEIJIN LIMITED (JP) | 1981-10-13 | — | — | US | claimed |
| EP-0023359-A2 | Powdery pharmaceutical composition and powdery preparation for application to the nasal mucosa, and method for administration thereof | TEIJIN LIMITED (JP) | 1981-02-04 | — | — | EP | claimed |
| US-4232002-A | Procedures and pharmaceutical products for use in the administration of antihistamines | THE WELSH NATIONAL SCHOOL OF MEDICINE (GB) | 1980-11-04 | — | — | US | claimed |